LifeStance Q2 revenue $345.3M (+11% YoY); raises FY 2025 Adj. EBITDA guidance to $140-150M

LifeStance Health Group, Inc.

Revenue of $345.3M (+11% YoY); net loss narrowed to $3.8M from $23.3M.
Adjusted EBITDA of $34.0M (+19% YoY); Free Cash Flow of $56.6M, a quarterly record.
Clinician base grew 11% to 7,708 (net +173 in Q2); visit volumes up 12% to 2.2M.
FY 2025 guidance: Adj. EBITDA raised to $140-150M (midpoint +$5M); revenue reiterated $1.40-1.44B.
Q3 2025 guidance: revenue $345-365M, Adj. EBITDA $33-39M, Center Margin $105-119M.

item 2.02item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.